Friday, July 21, 2017

Medical Cannabis Producer Plant Cap and CBD Strains


Research on the benefits of tetrahydrocannabinol (THC) and cannabidiol (CBD) in isolation is well established. Given the fact that tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most prominent chemical compounds in the cannabis plant, the vast majority of research to date has focused on the ratio of these two cannabinoids. THC demonstrates analgesic, anti-emetic, and anti-inflammatory properties, whereas CBD possesses anti-psychotic, anti-seizure, and anti-anxiety properties. The most recent research into THC:CBD ratios comes from GW Pharmaceuticals‘ Sativex, which has a 1:1 ratio of THC and CBD. In the clinical trials phase of drug development, researchers examined the effects of THC, CBD, and combination extracts on sleep, pain control, and muscle spasms. They found that 1:1 THC-CBD extracts provided the most therapeutic relief across all categories.
Revisions to the current licensing requirements for the plant count for patients and producers, in the New Mexico Medical Cannabis Program, that would remove the non-psychoactive cannabis CBD or hemp CBD strains, thus not counting them against patient, caregiver or producer allowable plant count. Cannabidiol, CBD, is a cannabis compound that has significant medical benefits, but does not make people have the euphoric feeling like a potent THC strain and can actually counteract that psycho-activity aspect of THC. The fact that CBD-rich cannabis is non-psychoactive or less psychoactive than THC-dominant strains makes it a great option for patients looking for relief without disconcerting feelings of lethargy or dysphoria.

Medical Properties of CBD
Effects
Antiemetic
Reduces nausea and vomiting
Anticonvulsant
Suppresses seizure activity
Antipsychotic
Combats psychosis disorders
Anti-inflammatory
Combats inflammatory disorders
Anti-oxidant
Combats neurodegenerative disorders
Anti-tumoral/Anti-cancer
Combats tumor and cancer cells
Anxiolytic/Anti-depressant
Combats anxiety and depression disorders

The current plant count set at 450 plants allowed by each medical cannabis producers clearly cannot meet the demands of over 45,000 patients in the program. Complicating the matter further is, not all the medical cannabis producers in the program are growing the allotted 450 plants. If all LNPP’s were growing the 450 plants then there would be 15,750 plants available. New Mexico’s medical cannabis program saw a 75% increase in participants over the last year. The 2016/17 licensure list for the medical cannabis program shows a total of 13,800 medical cannabis plants licensed by the 35 producers for All registered program participants in the program. Currently the Department of Health and LNPP’s are in process of doing the 2017/2018 licensure list. A revision to allow for 450 THC plants and 450 CBD Strains with a 1:1 - CBD:THC ratio (allowing CBD ratio to go above one but keeping THC at 1 or less in the ratio of potency)
13,800 medical cannabis plants divided by 45,000 registered program participants
Equals 0.31 medical cannabis plants per patient

Removing CBD strains from cannabis plants counts in New Mexico and other state programs for patients, caregivers and medical cannabis producers allowable plant count just makes sense. A patent was already awarded to part of the federal government, the U.S. Health and Human Services in 2003 (US6630507) that covers the use of CBD as a treatment for various neurodegenerative and inflammatory disorders.
Since cannabis contains medicinal compounds recognized and endorsed by an agency of the U.S. government- Why is it that cannabis remains on the Federal Schedule One list of drugs?

Removing CBD plant strains from the state’s program plant counts would allow for patients with a personal production license to empower themselves and their own grows with more CBD cannabis plants. The addition of patient run Cooperatives/Collectives could also be established and be able to support more medicine for the patient. For the producer growing medical cannabis, this would allow for 450 THC cannabis plants while still being able to provide enough CBD cannabis plants - removing that decision of growing what may sell more compared to what meets the medical needs of ALL the patients.

The fact that CBD-rich cannabis is non-psychoactive or has less psychoactive strains than THC-dominant strains makes it a great option for patients looking for relief without disconcerting feelings of lethargy or dysphoria.

Medical Cannabis CBD & Hemp CBD strains at ratio of;  1.1 THC (or lower) : 1 CBD (or higher) not counted against total allowed medical cannabis plants for the Patient PPL and the LNPP allowable plant count. And the establishment of an monthly allotment for Clones and Cuttings provided to qualified patient / caregiver with a PPL by a LNPP’s that is not counted against LNPP allowable plant count would provide great relief while the adequate supply matter is resolved. To do otherwise could leave a lot of sick people without viable medical solutions.

It’s really important for all people within the cannabis community to know they are the power; the government, legislators & policy makers are lead to us and We have the power to change the laws and government - people in it, policy being written, and overturning rules & regulations that disrupt safe access to our medicine. Not one state’s medical cannabis law is perfect, they are working pieces of democracy and this is where WE can establish patient lead policy in New Mexico and other states. We have the science, the research, the knowledge - the information the policy makers need to have and we need to get it in front of legislators and state regulators of the medical cannabis program.

No comments:

Post a Comment